Latest news

Alvotech today announced the appointment of Tanya Zharov as deputy chief executive officer in Iceland. Tanya's principal responsibilities will be oversight of Icelandic operations and administration, including the Reykjavik site...

Alvotech is developing AVT02 as a proposed biosimilar to HUMIRA® (adalimumab) with high concentration (100mg/mL) dosage forms The Phase 1 PK similarity study for AVT02 (AVT02-GL-101) has met its primary...

We are excited to announce the launch of our new brand identity for our B2B business, Adalvo. Why ‘Adalvo’? Our B2B business has seen tremendous growth in recent...

Alvotech Hf and DKSH, a leading healthcare provider across 36 emerging countries in South-East Asia, today announced that Alvotech Hf and DKSH have entered into an exclusive license partnership for...

To our patients, partners and communities around the world With the outbreak of the Coronavirus, our daily lives are changing. We are constantly monitoring developments to understand how we...

Alvotech and JAMP Pharma have entered into an agreement for an exclusive partnership to supply and commercialize five leading biosimilar candidates in the Canadian market. The current market value of...

Bang on Target! Over 40 managers from Alvotech and Alvogen made their way to CPhI in Frankurt last week. CPhI is one of the most important events for the industry...

Peter Goldschmidt, Róbert Wessman, Mark Levick

Alvotech announced today that Abu Dhabi-based investment company, Yas Holding, has acquired a 2.5% stake in their business and signed an agreement for the exclusive partnership and supply of three...

Alvotech has appointed Joseph Edward McClellan as its new Chief Scientific Officer. McClellan will be leading the company’s R&D functions, with overall responsibility for bringing products to market through its...

This promises to be a busy and exciting fall for Alvotech. Once more it will be participating in the world's largest pharmaceutical fair, CPhI, which this year is being hosted...

Alvotech and Prestige Biopharma, today announced a new contract manufacturing partnership for one of Prestige Biopharma´s biosimilar candidates.

Alvotech and Cipla Gulf FZ LLC (“Cipla Gulf”), a wholly-owned subsidiary of the leading global pharmaceutical company Cipla Limited (BSE: 500087; NSE: CIPLA EQ; hereafter referred to as "Cipla"), today...

Alvotech AVT02 is developed as a high concentration (100mg/mL) formulation, expected to be more convenient for patients, differentiating from most biosimilar competitors 407 participants enrolled in the Phase III study,...

Alvotech and Abdi Ibrahim enter into an exclusive partnership for the development and commercialization of biosimilars in Turkey. Alvotech gains access to the fast-growing Turkish biosimilar market Abdi Ibrahim is...

Alvotech today announced the appointment of Mark Levick as Chief Executive Officer, effective 5 August 2019. Mark brings over 18 years of global industry experience, with a very impressive track...

Alvotech and Fuji pharma have entered into a binding agreement for the exclusive partnership and supply to commercialize Alvotech’s ustekinumab biosimilar (Stelara®) in Japan.  Alvotech and Fuji Pharma recently announced...

Alvotech enrolls first patient in clinical phase III study involving biosimilar version of HUMIRA® Alvotech’s AVT02 is being developed as a biosimilar of the HUMIRA® high-concentration (100mg/mL) product, expected to...

Following the late 2018 announcement that Alvotech was to enter into a joint venture with Changchun High & New Technology Industries Group Inc (“CCHN”), representatives from the two companies met...

Fuels growth and biosimilar development in a fast-growing market Alvotech announced today that it has successfully raised US$300 million through a private bond offering. Net proceeds from the capital raised...

Biopharmaceutical company Alvotech announced today that Japan-based Fuji Pharma has acquired a 4.2% stake in the business for approximately US$50 million. Alvotech and Fuji Pharma recently announced an exclusive...